Patents by Inventor Liam O'Mahony

Liam O'Mahony has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIFIDOBACTERIUM LONGUM ABLE TO BENEFICIALLY MODULATE IMMUNE RESPONSE TO RESPIRATORY VIRUS INFECTION
    Publication number: 20230210921
    Abstract: Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of a respiratory viral infection in a subject. They are also useful in the prophylaxis of a secondary bacterial infection associated with a respiratory viral infection in a subject, especially a subject who is susceptible to respiratory infections.
    Type: Application
    Filed: December 6, 2022
    Publication date: July 6, 2023
    Applicant: PrecisionBiotics Group Limited
    Inventors: Barry KIELY, Liam O'MAHONY, David GROEGER
  • Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
    Patent number: 11590179
    Abstract: Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of a respiratory viral infection in a subject. They are also useful in the prophylaxis of a secondary bacterial infection associated with a respiratory viral infection in a subject, especially a subject who is susceptible to respiratory infections.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: February 28, 2023
    Assignee: PrecisionBiotics Group Limited
    Inventors: Barry Kiely, Liam O'Mahony, David Groeger
  • Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
    Patent number: 11529381
    Abstract: An isolated strain of Bifidobacterium longum NCIMB 42020 is useful for the treatment of viral infections, especially viral respiratory infections such as influenza, rhinovirus and RSV. Bifidobacterium longum NCIMB 42020 is also useful for clearing secondary bacterial infections.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: December 20, 2022
    Assignee: PrecisionBiotics Group Limited
    Inventors: Barry Kiely, Liam O'Mahony, David Groeger
  • PROBIOTIC BIFIDOBACTERIUM STRAIN
    Publication number: 20220169976
    Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.
    Type: Application
    Filed: December 8, 2021
    Publication date: June 2, 2022
    Applicant: PRECISIONBIOTICS GROUP LIMITED
    Inventors: Liam O'Mahony, Barry Kiely, John Francis Cryan, Timothy Dinan, Eileen Frances Murphy
  • Probiotic strain
    Patent number: 11225641
    Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: January 18, 2022
    Assignee: PrecisionBiotics Group Limited
    Inventors: Liam O'Mahony, Barry Kiely, John Francis Cryan, Timothy Dinan, Eileen Frances Murphy
  • MODULATION OF TISSUE FATTY ACID COMPOSITION OF A HOST BY HUMAN GUT BACTERIA
    Publication number: 20210163878
    Abstract: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.
    Type: Application
    Filed: December 14, 2020
    Publication date: June 3, 2021
    Applicants: PrecisionBiotics Group Limited, University College Cork, National University of Ireland, Teagasc - The Agriculture and Food Development Authority
    Inventors: Liam O'Mahony, Fergus Shanahan, Eamonn Quigley, Paul Ross, Catherine Stanton
  • Use of for treating inflammatory conditions
    Patent number: 10960032
    Abstract: The invention relates to use of Akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and/or obesity, especially for example undesirable airway inflammatory activity as seen with asthma.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: March 30, 2021
    Assignee: SCHWEIZERISCHES FORSCHUNGSINSTITUT FÜR HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS
    Inventors: Liam O'Mahony, Cezmi A. Akdis, David Michalovich, Edith M. Hessel, James R. Brown, David N. Mayhew, Sorif Uddin
  • BIFIDOBACTERIUM LONGUM
    Publication number: 20200377961
    Abstract: The multiple embodiments described herein comprise the genome of a probiotic Bifidobacterium longum bifidobacteria strain and genes encoded by the genome. Various novel Bifidobacterium longum are described.
    Type: Application
    Filed: May 12, 2020
    Publication date: December 3, 2020
    Applicant: PrecisionBiotics Group Limited
    Inventors: Douwe Van Sinderen, Jun Xu, Wenzhu Zhao, Raymond A. Grant, Yuli Song, Charles Bascom, Duane Larry Charbonneau, Liam O'Mahony
  • PROBIOTIC BIFIDOBACTERIUM STRAIN
    Publication number: 20200325548
    Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.
    Type: Application
    Filed: February 13, 2020
    Publication date: October 15, 2020
    Applicant: PRECISIONBIOTICS GROUP LIMITED
    Inventors: Liam O'MAHONY, Barry KIELY, John Francis CRYAN, Timothy DINAN, Eileen Frances MURPHY
  • Patent number: 10689719
    Abstract: The multiple embodiments described herein comprise the genome of a probiotic Bifidobacterium longum bifidobacteria strain and genes encoded by the genome. Various novel Bifidobacterium longum are described.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 23, 2020
    Assignee: PrecisionBiotics Group Limited
    Inventors: Douwe Van Sinderen, Jun Xu, Wenzhu Zhao, Raymond A. Grant, Yuli Song, Charles Bascom, Duane Larry Charbonneau, Liam O'Mahony
  • USE OF AKKERMANSIA MUCINIPHILA FOR TREATING INFLAMMATORY CONDITIONS
    Publication number: 20200164003
    Abstract: The invention relates to use of Akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and/or obesity, especially for example undesirable airway inflammatory activity as seen with asthma.
    Type: Application
    Filed: December 3, 2019
    Publication date: May 28, 2020
    Applicant: SCHWEIZERISCHES FORSCHUNGSINSTITUT FUR HOCHGEBRIGSKLIMA UND MEDIZIN IN DAVOS
    Inventors: Liam O'Mahony, Cezmi A. Akdis, David Michalovich, Edith M. Hessel, James R. Brown, David N. Mayhew, Sorif Uddin
  • BIFIDOBACTERIUM LONGUM
    Publication number: 20200115685
    Abstract: A formulation comprising an ingestible carrier and an isolated strain of Bifidobacterium longum.
    Type: Application
    Filed: November 8, 2019
    Publication date: April 16, 2020
    Applicant: Alimentary Health Ltd.
    Inventors: Jose Carlos GARCIA-GARCIA, Michael John Janusz, Barry Kiely, Eileen Frances Murphy, Liam O'Mahony
  • Probiotic bifidobacterium strain
    Patent number: 10597739
    Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: March 24, 2020
    Assignee: PrecisionBiotics Group Limited
    Inventors: Liam O'Mahony, Barry Kiely, John Francis Cryan, Timothy Dinan, Eileen Frances Murphy
  • Use of for treating inflammatory conditions
    Patent number: 10537597
    Abstract: The invention relates to use of Akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and/or obesity, especially for example undesirable airway inflammatory activity as seen with asthma.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: January 21, 2020
    Assignee: Schweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In Davos
    Inventors: Liam O'Mahony, Cezmi A. Akdis, David Michalovich, Edith M. Hessel, James R. Brown, David N. Mayhew, Sorif Uddin
  • BIFIDOBACTERIUM LONGUM ABLE TO BENEFICIALLY MODULATE IMMUNE RESPONSE TO RESPIRATORY VIRUS INFECTION
    Publication number: 20200016220
    Abstract: Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of a respiratory viral infection in a subject. They are also useful in the prophylaxis of a secondary bacterial infection associated with a respiratory viral infection in a subject, especially a subject who is susceptible to respiratory infections.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 16, 2020
    Applicant: Alimentary Health Limited
    Inventors: Barry KIELY, Liam O'MAHONY, David GROEGER, Raymond Alan GRANT, David MICHALOVICH, Edith M. HESSEL, Richard A. WILLIAMSON
  • BIFIDOBACTERIUM LONGUM ABLE TO BENEFICIALLY MODULATE IMMUNE RESPONSE TO RESPIRATORY VIRUS INFECTION
    Publication number: 20200000859
    Abstract: An isolated strain of Bifidobacterium longum NCIMB 42020 is useful for the treatment of viral infections, especially viral respiratory infections such as influenza, rhinovirus and RSV. Bifidobacterium longum NCIMB 42020 is also useful for clearing secondary bacterial infections.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 2, 2020
    Applicant: Alimentary Health Limited
    Inventors: Barry KIELY, Liam O'MAHONY, David GROEGER
  • Patent number: 10519430
    Abstract: A formulation comprising an ingestible carrier and an isolated strain of Bifidobacterium longum.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: December 31, 2019
    Assignee: Alimentary Health Ltd.
    Inventors: Jose Carlos Garcia-Garcia, Michael John Janusz, Barry Kiely, Eileen Frances Murphy, Liam O'Mahony
  • MODULATION OF TISSUE FATTY ACID COMPOSITION OF A HOST BY HUMAN GUT BACTERIA
    Publication number: 20190264168
    Abstract: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.
    Type: Application
    Filed: December 3, 2018
    Publication date: August 29, 2019
    Applicants: University College Cork, National University of Ireland, Teagasc- The Agriculture and Food Development Authority, Alimentary Health Ltd.
    Inventors: Liam O'Mahony, Fergus Shanahan, Eamonn Quigley, Paul Ross, Catherine Stanton
  • Bifidobacterium longum
    Publication number: 20190153408
    Abstract: A formulation comprising an ingestible carrier and an isolated strain of Bifidobacterium longum.
    Type: Application
    Filed: February 4, 2019
    Publication date: May 23, 2019
    Inventors: Jose Carlos Garcia-Garcia, Michael John Janusz, Barry Kiely, Eileen Frances Murphy, Liam O'Mahony
  • Patent number: 10233433
    Abstract: A formulation comprising an ingestible carrier and an isolated strain of Bifidobacterium longum.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: March 19, 2019
    Assignees: Alimentary Health Ltd., The Procter & Gamble Company
    Inventors: Jose Carlos Garcia-Garcia, Michael John Janusz, Barry Kiely, Eileen Frances Murphy, Liam O'Mahony